First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

10.1136/jitc-2021-002863

Saved in:
Bibliographic Details
Main Authors: Piha-Paul, Sarina A, Geva, Ravit, Tan, Tira J, Lim, Darren Wt, Hierro, Cinta, Doi, Toshikiko, Rahma, Osama, Lesokhin, Alexander, Luke, Jason John, Otero, Javier, Nardi, Lisa, Singh, Angad, Xyrafas, Alexandros, Chen, Xinhui, Mataraza, Jennifer, Bedard, Philippe L
Other Authors: DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format: Article
Published: BMJ 2022
Subjects:
antibodies
clinical trials as topic
combination
drug therapy
investigational
neoplasm
therapies
Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Dose-Response Relationship, Drug
Female
Glucocorticoid-Induced TNFR-Related Protein
Humans
Immune Checkpoint Inhibitors
Lymphoma
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms
Online Access:https://scholarbank.nus.edu.sg/handle/10635/218496
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Internet

https://scholarbank.nus.edu.sg/handle/10635/218496

Similar Items